Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Bristol's Sale Of HIV Pipeline To ViiV Signals Tightened Focus

This article was originally published in Scrip

Executive Summary

Bristol-Myers Squibb Co. on Dec. 18 took another step in narrowing its therapeutic focus by selling its pipeline of HIV candidates, including novel Phase III and Phase IIb assets, to ViiV Healthcare in a pair of deals bringing $350m in upfront cash and significant earn-out potential back to the US-based pharma.


Related Content

Novel Antibody Products Ring The Treatment Changes In HIV
Is Gilead Vulnerable to ViiV As It Nears End Of HIV R&D Activity?
ICYMI: Biogen, GSK And Roche Slip Pipeline Setbacks Into Earnings Reports